Anti-Human IL-33 - Biotin

IL-33 is expressed by a wide variety of cell types, including fibroblasts, mast cells, dendritic cells, macrophages, osteoblasts, endothelial cells, and epithelial cells.

Biotin

This biotinylated antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 50 ug of bovine serum albumin per ug of antibody with no calcium, magnesium, or preservatives present.

This biotinylated antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 50 ug of bovine serum albumin per ug of antibody with no calcium, magnesium, or preservatives present.

Purified Recombinant Human IL-33 (Accession No.: O95760)

IL-33 is a 30 kD proinflammatory cytokine that belongs to the IL-1 superfamily. It signals inflammation in the body via the stimulation of macrophages, neutrophils, B cells, Th2 cells, eosinophils, basophils and mast cells. IL-33 is a ligand for IL33R (ST2), which is part of a cytokine receptor gene cluster that includes IL-1RI and IL-1RII. IL-33 binds ST2 and complexes with the IL-1R Accessory Protein (IL-1R-AcP) to form a functional signaling receptor complex facilitating the activation of NF-?B and MAP kinase signaling pathways resulting in the production of type 2 cytokines from polarized Th2 cells. IL-33R can exist as a type I transmembrane glycoprotein or a soluble glycoprotein. The soluble IL-33R is thought to serve as a decoy receptor which competitively antagonizes the binding of IL-33 thereby reducing its biological effects. IL-33 has been linked with asthma, allergies, endometriosis, and hay fever. In addition, IL-33 resides in keratinocytes of the skin and is thought to trigger the itching associated with dermatitis when subjected to irritation or allergic conditions. Furthermore, in APP/PS1 mice, IL-33 has been shown to be effective in reversing the buildup and preventing the new formation of amyloid plaques that are characteristic of Alzheimer?s disease. However, the action of extracellular IL-33 is limited due to rapid oxidation that causes a molecular conformational change which prevents it from binding to the ST2 receptor.

90865

IL-33